Trials / Completed
CompletedNCT01564459
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 in Patients With Painful Diabetic Neuropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of MK-6096 in the treatment of painful diabetic neuropathy (PDN) in adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-6096 | MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days. |
| DRUG | Placebo | Matching compressed tablets, taken once daily at bedtime for 14 days. |
Timeline
- Start date
- 2012-03-26
- Primary completion
- 2013-04-18
- Completion
- 2013-04-18
- First posted
- 2012-03-27
- Last updated
- 2018-11-07
- Results posted
- 2016-08-10
Source: ClinicalTrials.gov record NCT01564459. Inclusion in this directory is not an endorsement.